Rare Case: Tirzepatide Linked to Immune Thrombocytopenia
Background
Tirzepatide is a popular dual GIP/GLP-1 receptor agonist widely used for managing type 2 diabetes and obesity. While generally well-tolerated, all medications carry a risk of adverse effects. This case report investigates a rare instance of Tirzepatide potentially causing immune thrombocytopenia (ITP), a serious autoimmune blood disorder characterized by low platelet counts.
Results
The patient presented with a significantly low platelet count of 12,000/µL (normal range: 150,000-450,000/µL) approximately 6 weeks after starting Tirzepatide. Initial treatment with corticosteroids and intravenous immunoglobulin (IVIG) led to a temporary increase in platelet count to 50,000/µL, but it subsequently dropped again within 1 week. Upon discontinuation of Tirzepatide, the patient's platelet count showed a sustained recovery, reaching 180,000/µL within 3 weeks without further specific ITP treatment. This rapid and sustained recovery post-discontinuation, compared to the transient effects of other treatments, strongly suggests a drug-induced etiology for the ITP. Re-challenge with Tirzepatide was not performed due to the clear temporal association and the severity of the initial presentation.
Why It Matters
This case highlights a potentially rare but serious adverse effect of Tirzepatide, warranting increased awareness among clinicians. Recognizing drug-induced ITP is crucial for timely discontinuation of the offending agent and appropriate management to prevent severe bleeding complications. While this is a single case, it suggests that patients on Tirzepatide who develop unexplained thrombocytopenia should be evaluated for drug-induced ITP. Further post-marketing surveillance and potentially larger observational studies are needed to determine the true incidence and mechanism of this adverse event.